Health ❯ Preventive Medicine ❯ Risk Factors ❯ Cardiovascular Health
The aldosterone‑synthesis inhibitor cut systolic readings by roughly 9–10 mmHg versus placebo in the BaxHTN trial, prompting plans for regulatory submissions.
